<DOC>
	<DOCNO>NCT02861222</DOCNO>
	<brief_summary>The purpose study determine toxicity tolerance Myocet® child adolescents refractory relapse malignant glioma , dose diminished 20 % dose recommend adult dose recommended adult , administer single dose 1-hour perfusion 21 day . Other purpose determine recommend dose Myocet ass response drug . Pharmacokinetics doxorubicin ( free encapsulate form ) metabolite doxorubicinol 72 hour Myocet administration also study .</brief_summary>
	<brief_title>Myocet® Children With Relapsed Refractory Non-brainstem Malignant Glioma</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>Patients receive least one cycle chemotherapy radiotherapy Patients grade III IV ( WHO ) glioma , localized brainstem Tumor measurable magnetic resonance image Absence concomitant anticancer treatment Absence chemotherapy 4 week ; 6 week nitrosourea Good general health nutritional status accord NCICTC scale ( version 3 ) ( appendix 6 ) Lansky score &gt; 50 % Karnofsky &gt; 50 child old 12 year Absence organ toxicity ( grade &gt; 2 accord NCICTC criterion ( version 3 ) Hematology : polynuclear neutrophil count &gt; 1.0 x 109/l Hematology : platelet count &gt; 100 x 109/l Liver function : bilirubinemia &lt; 1.5 normal value Liver function : ASAT ALAT level &lt; 2.5 normal value Liver function : prothrombin level &gt; 70 % Liver function : fibrinogen &gt; 1.5 g/l Renal function : creatinemia &lt; 1.5 normal value/age Cardiac function : EF &gt; 60 % and/or SF &gt; 30 % Signature inform consent patient adolescent , 2 parent legal guardian minor patient For patient childbearing potential , contraceptive method compulsory . This contraception must continue 6 month Myocet treatment end For patient childbearing potential , negative pregnancy test ( betahCG test ) Non compliance eligibility criterion Severe lifethreatening infection Non control evolutive symptomatic intracranial hypertension History Myocet treatment , patient could treat anthracyclines cardiac function normal Hypersensibility active substance , premixtures one excipients Pregnancy breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>